Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2021 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UIPATH INC | 9 | Q3 2023 | 30.2% |
DOORDASH INC | 9 | Q3 2023 | 19.6% |
SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
908 DEVICES INC | 9 | Q3 2023 | 1.8% |
TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-14 |
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-15 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-13 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.